Figure 6.

(A) Inhibition of the binding of soluble dimeric vascular endothelial growth factor A (VEGF-A) to its receptor by the intact monoclonal bivalent antibody mAb1 (EC50 = 1.2 nM), mAb1 digested with GingisKHAN™ (EC50 = 10.3 nM), a purified mAb1 Fab obtained by an in-solution papain digest (EC50 = 10.4 nM), an intact (EC50 = 12.1 nM) and GingisKHAN™-digested (EC50 = 12.5 nM) bispecific VEGF-A-monovalent mAb1 derived 1+1 CrossMab, and the GingisKHAN™ protease alone (negative control), as measured by a VEGF-A-specific reporter gene assay. (B) Inhibition of the binding of multimeric angiopoitin-2 (Ang-2) to the tyrosine kinase receptor (Tie-2) by the intact monoclonal antibody mAb2 (EC50 = 3.0 nM), mAb2 digested with GingisKHAN™ (EC50 = 36 nM), and a bispecific Ang-2 monovalent mAb2 derived 1+1 CrossMab (EC50 = 57 nM), as measured by a cell-based Tie-2 receptor phosphorylation assay.